Hemi-Gland Cryoablation for Prostate Cancer at UCLA
This is a prospective data collection of men who are electing to undergo prostate hemi-gland cryoablation.
The purpose of this observational research study is to investigate the localized treatment of prostate cancer using hemi-gland cryoablation.
UCLA patients undergoing hemi-gland cryoablation are a unique cohort compared to prior research because all patients at UCLA have had a pre-treatment multi-parametric MRI and Ultrasound fusion targeted biopsy; they will be followed in a similar fashion. This results in more precise assessment of a target region of cancer for ablation which may, in turn, result in improved clinical outcomes.
|Condition or Disease||Intervention/Treatment||Phase|
Primary Outcome Measures
- Clinical Response to Cancer Treatment [6 months]
Our primary endpoint will be a patient's clinical response to cancer treatment, specifically, the degree of prostate cancer on a post-treatment fusion biopsy compared to pre-treatment.
Secondary Outcome Measures
- Quality of Life Assessment - Urinary Function [6 months]
Comparison of urinary function pre- and post-treatment will be obtained using the International Prostate Symptom Score (IPSS) and the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaires to report combined overall urinary function assessments.
Other Outcome Measures
- Quality of Life Assessment - Erectile Function [6 months]
Comparison of erectile function pre- and post-treatment will be obtained using the 5-Item International Index of Erectile Function (IIEF-5) Sexual Health Inventory for Men and the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaires to report combined overall erectile function assessments.
Patient has undergone or has elected to undergo hemi-gland cryoablation at UCLA
Low or intermediate risk prostate cancer (Gleason ≤ 7) or select high-risk patients (Gleason 8 prostate cancer).
Prostate volume of ≤ 70 cc
Ability to complete informed consent form
Medical contraindication to follow-up multi-parametric magnetic resonance imaging (mpMRI) or prostate biopsy
Patients unable to tolerate general or regional anesthesia.
Contacts and Locations
|1||University of California, Los Angeles||Los Angeles||California||United States||90095|
Sponsors and Collaborators
- Jonsson Comprehensive Cancer Center
- Principal Investigator: Leonard S Marks, MD, University of California, Los Angeles
Study Documents (Full-Text)None provided.